Related Experiment Video
Updated: Oct 11, 2025
Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
Published on: March 22, 2024
The Thioredoxin-1 Inhibitor, PX-12, Suppresses Local Osteosarcoma Progression
Hideyuki Kinoshita1, Osamu Shimozato2, Takeshi Ishii3
1Department of Orthopedic Surgery, Chiba Cancer Center, Chiba, Japan; kinoshi1783@yahoo.co.jp.
Background/Aim:
The thioredoxin-1 (Trx-1) inhibitor, PX-12, is active against several cancer types. This study aimed to evaluate its effects on local osteosarcoma (OS) progression and to describe PX-12-related signal transduction pathways.
Materials And Methods:
Publicly available expression cohort data were analyzed to determine the relationship between the expression levels of TXN, which codes for the Trx protein, and survival in patients with OS. Murine LM8 OS cells were stimulated with PX-12. Apoptosis-related protein levels, cell viability, caspase activity, and wound healing were evaluated. PX-12 efficacy in suppressing tumor progression was evaluated in C3H mice injected with LM8 cells.
Results:
High TXN expression was a negative prognostic factor for metastasis and overall survival in OS patients. PX-12 induced apoptosis in OS cells via the oxidative stress-MAPK-caspase 3 pathway and suppressed OS cell migration. PX-12 suppressed local OS progression.
Conclusion:
PX-12 is a potential therapeutic agent for use in suppressing local OS progression.
